Immunic Inc
NASDAQ:IMUX

Watchlist Manager
Immunic Inc Logo
Immunic Inc
NASDAQ:IMUX
Watchlist
Price: 0.997 USD 6.52% Market Closed
Market Cap: 95.5m USD

EV/EBITDA
Enterprise Value to EBITDA

-0.7
Current
-0.2
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.7
=
Enterprise Value
75.6m USD
/
EBITDA
-100.8m USD
Market Cap EV/EBITDA
DE
Immunic Inc
NASDAQ:IMUX
89.9m USD -0.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -194 789.6
US
Abbvie Inc
NYSE:ABBV
336.1B USD 15.4
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 213.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 14.8
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 10.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD 26
US
Epizyme Inc
F:EPE
94.1B EUR -580
AU
CSL Ltd
ASX:CSL
129.7B AUD 18.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 12.1
US
Seagen Inc
F:SGT
39.3B EUR -66.5
EBITDA Growth EV/EBITDA to Growth
DE
Immunic Inc
NASDAQ:IMUX
Average EV/EBITDA: 16.3
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 789.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580 N/A N/A
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A